The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia
The expression of serum sEGFR, sFlt-1, sEndoglin and PLGF in preeclampsia
复制标题
子痫前期血清sEGFR、sFlt-1、sEndoglin、PLGF的表达
DOI：
10.1016/j.preghy.2018.05.011
复制
发表时间：
2018-07-01
影响因子：
2.2
通讯作者：
Li, Yulin
中科院分区：
文献类型：
--
作者：
Cui, Lifeng;Shu, Chang;Li, Yulin
本研究的目的是调查正常血压、早产和足月子痫前期妊娠血清中可溶性表皮生长因子受体 (sEGFR)、可溶性血管内皮生长因子受体 1 (sFlt-1)、可溶性内皮糖蛋白 (sEndoglin) 和胎盘生长因子 (PLGF) 的浓度，从而明确这些生化标志物在监测严重程度和严重程度方面的临床应用。 早产儿先兆子痫的宫内生长迟缓。 172 名孕妇被分为以下几组：早产先兆子痫组、早产对照组、足月先兆子痫组和足月对照组。早产先兆子痫患者按严重特征（n = 50）和无严重特征（n = 22）进行分层。使用 Luminex 多重免疫测定法评估 sEGFR、sEndoglin 和 PLGF，而使用 ELISA 评估 sFlt-1。早产先兆子痫中的 sEGFR 显着低于匹配对照 (p < 0.001)，足月先兆子痫中的 sEGFR 略低于匹配对照 (p < 0.01)。相反，早产先兆子痫中的 sFlt-1 显着高于匹配对照 (p < 0.001)，足月先兆子痫中的 sFlt-1 略高于匹配对照 (p < 0.01)。 sFlt-1、sFlt-1/sEGFR、sFlt-1/PLGF与早产子痫前期严重程度呈正相关（P<0.001，R值≥0.6），其中sFlt-1/sEGFR的R值最高（R值=0.711）。此外，sEndoglin 和 sEndoglin/sEGFR 比值与早产先兆子痫组中小于胎龄的新生儿出生体重 (SGA，n = 25) 相关。结论：sFlt-1/sEGFR比值可作为监测早产先兆子痫严重程度的新候选生化标志物。 sEndoglin和sEGFR可能参与早产子痫前期SGA的发病机制。
The objective of this study was to investigate soluble epidermal growth factor receptor (sEGFR), soluble vascular endothelial growth factor receptor 1 (sFlt-1), soluble endoglin (sEndoglin) and placenta growth factor (PLGF) concentrations in normotensive, preterm and term preeclamptic pregnancies' serum and thus to specify the clinical utility of these biochemical markers in monitoring severity and intrauterine growth retardation of preterm preeclampsia. 172 pregnant women were divided into the following groups: preterm preeclampsia, preterm control, term preeclampsia and term control. Preterm preeclampsia patients were stratified with severe feature (n = 50) and without severe feature (n = 22). sEGFR, sEndoglin and PLGF were assessed using Luminex multiplex immunoassay, whilesFlt-1 was assessed using ELISA. sEGFR was significantly lower in preterm preeclampsia than matched control (p < 0.001) and mildly lower in term preeclampsia than matched control (p < 0.01). On contrary, sFlt-1 was significantly higher in preterm preeclampsia than matched control (p < 0.001) and mildly higher in term preeclampsia than matched control (p < 0.01). sFlt-1, sFlt-1/sEGFR and sFlt-1/PLGF were positively correlated with the severity of preterm preeclampsia (P < 0.001, R value >= 0.6), especially sFlt-1/sEGFR had the highest R value (R value = 0.711) among them. Furthermore, sEndoglin and the ratio of sEndoglin/sEGFR were associated with neonatal birth weight small for gestational age (SGA, n = 25) in preterm preeclampsia group. Conclusions: The ratio of sFlt-1/sEGFR could be used as a novel candidate biochemical marker in monitoring the severity of preterm preeclampsia. sEndoglin and sEGFR may be involved in the pathogenesis of SGA in preterm preelampsia.